Cancer

  • Vanderbilt University

    New cancer target could push new drugs into the clinic

    New work by Professor of Cell and Developmental Biology Bill Tansey and colleagues has determined that a new type of inhibitor—a WINi—targets cancer cells in a novel way and suggests exploiting this pathway in future anticancer drug development efforts. Read More

    May. 14, 2024

  • Vanderbilt University

    A Nobel-worthy discovery spawns a new field—and new therapies

    Cohen was awarded the 1986 Nobel Prize in Physiology or Medicine for his discovery of epidermal growth factor, a protein produced in the body that influences the development of nerve and skin tissues by stimulating cell growth and differentiation. The discovery of EGF launched an entire field of research into growth factor signaling and had major impacts on human health. Read More

    Mar. 7, 2024

  • Vanderbilt University

    Cell and Developmental Biology pushes the limits of cancer research

    If you had visited Vanderbilt nearly a century ago searching for cellular research, you would have found yourself in the Department of Anatomy. Established in 1925, the Department of Anatomy gave way to the Department of Cell Biology before taking on its current moniker—Cell and Developmental Biology—in 2001. Read More

    Mar. 7, 2024

  • Vanderbilt University

    Study reveals critical first steps to cancer

    As cells grow and divide, their DNA needs to be accurately replicated and properly segregated to new cells. Errors during replication or segregation can alter the genome and promote cancer. Now, researchers at Vanderbilt University Medical Center have identified the mechanism by which the enzyme and tumor suppressor SETD2 prevents… Read More

    Sep. 28, 2023

  • Vanderbilt University

    Neil Dani honored with prestigious 2023 Rita Allen Foundation Scholar award

    In a landmark achievement, Neil Dani, an assistant professor in the Department of Cell and Developmental Biology, has been named a 2023 Rita Allen Foundation Scholar. The prestigious grant program supports early-career biomedical scholars who adopt bold and innovative approaches to fundamental… Read More

    Aug. 24, 2023

  • Vanderbilt University

    Richmond lab identifies a key regulator of melanoma development

    By Kensey Bergdorf Ann Richmond In a continuation of previous work studying the role of chemokine receptor CXCR2 in immune cells published in Cancer Immunology Research, the lab of Ann Richmond, Ingram Professor of Cancer Biology and professor of pharmacology, has identified that same receptor as a regulator of melanoma… Read More

    Jun. 15, 2023

  • Leveraging the structure of bacterial host cell receptors to detect cancer

    Leveraging the structure of bacterial host cell receptors to detect cancer

    Bacteria in our bodies bind to various host cell surface receptors, which determines where the bacteria live and how they behave. These receptors, made up of chains of sugar molecules called glycans, are more than meets the eye. Cells existing within progressive disease states like cancer can have an increased… Read More

    Aug. 16, 2022

  • Vanderbilt University

    Attend ‘Survivor: Intersections of Cancer and Mental Health with Ethan Zohn’ on April 26

    Ethan Zohn, winner of the CBS reality show Survivor, two-time cancer survivor, humanitarian and former professional soccer player, will discuss his journey with reality television, cancer, mental health and humanitarian work as part of the School of Medicine Basic Sciences’ monthly Lab-to-Table Conversations on Tuesday, April… Read More

    Apr. 8, 2022

  • Vanderbilt University

    CD40 expression correlates with response to immunotherapy in melanoma patients

    L-R: Ann Richmond, Chi Yan By Wendy Bindeman Ann Richmond, professor of pharmacology, and Chi Yan, a research assistant professor in the Richmond lab, recently published a study showing that expression of a protein called CD40 can be used to predict response to immunotherapy in malignant melanoma. Read More

    Mar. 1, 2022